Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 5/20 | 0.62 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | TGM1 | P22735 | 1/20 | 0.50 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.50 |
| ▸ | CDK14 | O94921 | 2/20 | 0.49 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206198 | 0.95 | IRAK1 (0.65) | IRAK1MAP3K19TGM2LMNAF13A1 | |
| SCHEMBL20206122 | 0.90 | IRAK1 (0.65) | IRAK1MAP3K19TGM2LMNAF13A1 | |
| SCHEMBL20206121 | 0.86 | IRAK1 (0.64) | IRAK1MAP3K19TGM2CDK14CCNY | |
| SCHEMBL21328541 | 0.84 | IRAK1 (0.47) | IRAK1MAP3K19TGM2CDK14CCNY | |
| SCHEMBL21328542 | 0.84 | IRAK1 (0.47) | IRAK1MAP3K19TGM2CDK14CCNY | |
| SCHEMBL20190964 | 0.84 | IRAK1 (0.47) | IRAK1MAP3K19TGM2LMNAF13A1 | |
| SCHEMBL20189257 | 0.84 | POLB (0.55) | LMNAGRM5POLBGAAKDM4E | |
| SCHEMBL21345467 | 0.83 | IRAK1 (0.46) | IRAK1MAP3K19TGM2LMNAF13A1 | |
| SCHEMBL24021453 | 0.83 | GRM5 (0.48) | IRAK1LMNAGRM5POLBCHRNB2 | |
| SCHEMBL20206102 | 0.81 | GRM5 (0.55) | LMNAGRM5POLBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3544970-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098367-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098367-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885TGM2 3888/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885TGM2 3888/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885TGM2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.